Forskolin

Catalog No.S2449 Synonyms: Coleonol

Forskolin Chemical Structure

Molecular Weight(MW): 410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 270 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 20 Publications

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NWXBWVd6TnWwY4Tpc44hSXO|YYm= NXHxT3hoOTBizszN MmPZOkBp NWTMWVYzcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? M4jmUFI3PDN3NEm4
Mo-DCs MXnGeY5kfGmxbjDBd5NigQ>? MUC1NEDPxE1? Mn\5NlTjiImq Ml\IdJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh MlLXNlY1OTJ7NEi=
RBMECs  NVnKTFdmTnWwY4Tpc44hSXO|YYm= M3TPdVXDqM7:TR?= NVLTOpFUOcLiaB?= M1zCboJtd2OtczD0bIUhWmGlMTDpcoFkfGm4YYTpc44hcW6mdXPl[EBjgSCHTVHQMWlK MXyyOlM2QDB|OR?=
INA-6 MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWKwMVExOCEQvF2= MofJO|LjiImq NGi0emlqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M17pUFI3OzB4NkK0
OPM-2 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3LGdlAuOTByIN88US=> Mk\BO|LjiImq MUjpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MYiyOlMxPjZ{NB?=
U266 MmjhR4VtdCCYaXHibYxqfHliQYPzZZk> NVT6[4dqOC1zMECg{txO M3r3Slcz6oDLaB?= NGT4OVRqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> MlrmNlY{ODZ4MkS=
H929 MlXLR4VtdCCYaXHibYxqfHliQYPzZZk> NXX0UGxoOC1zMECg{txO MYm3NwKBkWh? NGS1V2RqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mlq3NlY{ODZ4MkS=
RPMI 8226 M1;mNGNmdGxiVnnhZoltcXS7IFHzd4F6 NH[3eVUxNTFyMDFOwG0> NIPRTVk4OuLCiXi= Mln2bY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= MmDINlY{ODZ4MkS=
MDCK  NWrNSnF7TnWwY4Tpc44hSXO|YYm= NYTk[GlHOTBiwsXN NIDES44zPCCq MWDEUXNQ NI\rOIZ2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCWR1[t{tIyKGGwZDDDWGdHyqB? M2W5VVI3OjB{M{Wy
MDCK  MnLJSpVv[3Srb36gRZN{[Xl? NY\Ie4VyOTBiwsXN MnO2NlQhcA>? M2XaV2ROW09? NGDEeHFqdmirYnn0d{B1cGViaX7jdoVie2WmIHX4dJJme3Orb36gc4YhTk5iY3H1d4VlKGK7IGTHSk3PujF? NH7s[IozPjJyMkO1Ni=>
Spinal cords  M3;uSmZ2dmO2aX;uJGF{e2G7 NIrVeHcyyqEQvF2= MXezNEBucW5? NGfVTpZ{fGmvdXzheIV{KGODTWCgcIV3\Wy| MUeyOlEzPjl{Nh?=
BeWo  M37QSmZ2dmO2aX;uJGF{e2G7 NEPre4QzPeLCid88US=> NUXWT|FqOjRxNEivO|IhcA>? NWnHc2g1dGWjZIOgeI8h[W5iaX7jdoVie2ViaX6geIhmKGW6cILld5Nqd25ib3[gc5Rp\XJiZoXzbY9vKG2jcnvldpM> M37seFI3ODV|NUS5
bovine oocytes NGnJN|lHfW6ldHnvckBCe3OjeR?= MnX4NVAxyqEQvF2= MkfDNVLDqGh? NFL1e5VqdmirYnn0d{B1cGViZX\m[YN1KG:oIF7QVGEh[W6mL3;yJG5RWENidH:gd5RqdXWuYYTlJJJme3WvcITpc44hd2ZibXXpc5Nqew>? M4HEPVI3ODVzNkGx
Caco-2  MYPGeY5kfGmxbjDBd5NigQ>? M1vFeVAvOS9zL{GwJO69VQ>? M4rLW|IxyqCvaX6= NXfofIJNcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ2FOWCCuZY\lcJM> MoThNlYxPDlzMEK=
Caco-2  M4fGdWZ2dmO2aX;uJGF{e2G7 MnjCNE4yNzFxMUCg{txO MmH5NlQhcA>? NFewZ3VqdmO{ZXHz[ZMhVVKSMjDwdo91\WmwIHzleoVt NVrOZYVzOjZyNEmxNFI>
AML-12  NWjWV5dVTnWwY4Tpc44hSXO|YYm= NYr2UWFOOjBizszN MUmzJIg> MlzXeZBz\We3bHH0[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcJMh[XRiVHjyMVQyOSCjbnSgV4VzNTR7Mx?= NWL5NJhJOjZyNEi5PFU>
AML-12  MWfGeY5kfGmxbjDBd5NigQ>? NE\OUXEzOCEQvF2= M33MO|EuQCCq NEL2dZpqdmO{ZXHz[ZMh\2y3Y3;z[UBxem:mdXP0bY9v M4[yOVI3ODR6OUi1
AML-12  M4O0fmZ2dmO2aX;uJGF{e2G7 MYeyNEDPxE1? MVKzJIg> NYjUPFZzfXBvcnXneYxifGW|wrDQ[4My[S{EoGDldINsNCCjbnVCpGc3eGQEoH3SUmEhdGW4ZXzz NYLmc49FOjZyNEi5PFU>
AML-12  NVHWSlBHTnWwY4Tpc44hSXO|YYm= MmfSNlAh|ryP NHTDTY4{KGh? MmCxbY5lfWOnczD0bIUh\GWyaH;zdIhwenmuYYTpc44hd2ZiQ2LUR|LDqA>? MViyOlA1QDl6NR?=
RBMECs NGTlc3BHfW6ldHnvckBCe3OjeR?= MnnnOeKh|ryP NF;je4cyKGh? M3myWolvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh M4ntW|I3ODR2Nk[z
EndoC-βH1 MXvGeY5kfGmxbjDBd5NigQ>? NIO3dog2yqEQvF2= NY\0U|V5OSCq NHzFXnpxd3SnboTpZZRmeyCpbIXjc5NmNWmwZIXj[YQhcW6|dXzpckB{\WO{ZYTpc44hcW5idHjlJJBz\XOnbnPlJI9nKGeudXPvd4U> MYGyOlAzQDV4Mh?=
EndoC-βH1 NUPQW4dpTnWwY4Tpc44hSXO|YYm= NXHPWJE4PcLizszN NH\hO3cyKGh? MmfYcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? NX\iXHdEOjZyMki1OlI>
SH-SY5Y NHLUUVhHfW6ldHnvckBCe3OjeR?= Mln2N|Ah|ryP NXjMXHJ6OzBibXnu NH\PSVdFVVOR M3LPN5Nq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> NGLjS4YzPjB{NUGzOy=>
PC-3 MnjwSpVv[3Srb36gRZN{[Xl? NYnvVZNGPDBiwsXN NFS0VXczKGh? M3rYcWROW09? MXjs[YFleyC2bzDQVFJCKGGldHn2ZZRqd25? NGPEUYIzPjB{M{izOi=>
PC-3 M3LMN2NmdGxiVnnhZoltcXS7IFHzd4F6 M1HGdFQxKML3TR?= MYWyOE81QC95MjDo M2ixfGROW09? Mn3r[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? NHHIWWszPjB{M{izOi=>
SCG M4\jZ2Z2dmO2aX;uJGF{e2G7 MVyyNEDPxE4EoB?= NFXIblJFVVOR NY\3V|U{emW4ZYLzbYJtgSC|dYDwdoV{e2W|IFnLWkB4cXSqIHGgTWM2OCCxZjCyOE41KM7:TR?= M2Dq[FI2QTZ{MUOy
HEK-293 Moj5SpVv[3Srb36gRZN{[Xl? MVmzOUDPxE4EoB?= NUKxfIRXTE2VTx?= MnrKbY5lfWOnczDhJINwdnOyaXP1c5V{KOLCnHnuZYN1cX[jdHnvcwKBpSCxZjD0bIUhU3Z{LkGgZ5VzemWwdB?= NV3WO4ZvOjV7NkKxN|I>
SCG NV[wN4NpTnWwY4Tpc44hSXO|YYm= NUfUOlVuOTByIN88UeKh M3\mVGROW09? NHe5WnFz\WS3Y3XzJJRp\SCneHPpeIFjcWyrdImgc4YhW0OJIH7leZJwdnN? MoPlNlU6PjJzM{K=
PCCL3 NUnnfZloTnWwY4Tpc44hSXO|YYm= MmnnNVAhyrWP NYjsS4o{OjRiaB?= MWrlcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? NXP0bWF[OjV7NkC5OVY>
3T3-L1 preadipocytes NHnM[4dHfW6ldHnvckBCe3OjeR?= NWPUPXZROTBizszNxsA> NGjESWIyOiCq M13P[Ylv\HWlZYOgR3JGSiCyaH;zdIhwenmuYYTpc44h[W6mIFOvSWJR|rJiZYjwdoV{e2mxbh?= MUGyOVkzQDB3OB?=
H295R  M{HaXWZ2dmO2aX;uJGF{e2G7 NHWzOFUyOMLizszN M2HYUFQ5yqCq NFrNVlRqdmO{ZXHz[ZMhe3Sncn;p[EBu\XSjYn;sbZRmeyCrbjD0bIUh[W6mcn;n[Y4tKG2rbnXyZYxwNSCjbnSg[4x2[2:lb4L0bYNwcWRicHH0bJdigXN? MmOyNlU5Pjl3NU[=
PBMC MUnGeY5kfGmxbjDBd5NigQ>? MoH4OVDDqM7:TR?= MV6yOOKhcMLi MkjFbY5pcWKrdIOgeIhmKGmwY4LlZZNm\CC|ZXPy[ZRqd25ib3[gWG5HKGmwZIXj[YQh[nlidHjlJGRRTQ>? Mn\HNlU5PjZyN{m=
GLUTag  M33mO2Z2dmO2aX;uJGF{e2G7 NVTxPXBMOTEkgJpCuW0> MUewM|IwPCCq MXfzeIlufWyjdHXzJGdNWC1zIIPlZ5JmfGmxbjDjc5Rz\WG2ZXSge4l1cCCLQl3Y MUmyOVg{OjZ|MR?=
GLUTag  M4DI[mZ2dmO2aX;uJGF{e2G7 NXTSTpd2OTEkgJpCuW0> M4PQTlQhcA>? MmTybY5kemWjc3XzJJRp\SCyQ2LFRkBt\X[nbIOge4l1cCC2aHWgTWJOYA>? M3n2XVI2QDN{NkOx
BAECs MmDqSpVv[3Srb36gRZN{[Xl? NHzRWJgzPSEQvF2= M{HLVlI1KGh? MnPi[Y5p[W6lZYOgeIhmKGGldHn2ZZRqd25ib3[gVHBCWs7zIHL5JFUh|ryPIILld5ZmemG2cn;sMEBVPEiVLDDvdkA1NVCDUB?= M2LaVFI2Pzl6OEK2
PC12 M4jWXmZ2dmO2aX;uJGF{e2G7 MkfGNlXDqM7:TR?= M1[4ZlQ5KGh? NFr4SWRi[3SrdnH0[ZMh[0GPUB?= MlOyNlU4Pjl|MEW=
GH3 NFHXbHZHfW6ldHnvckBCe3OjeR?= MUSxxsDPxE1? MXq2MYg> NVX6VWV[[XS2ZX71ZZRmeyC2aHWgZ49zemWuYYTpc44h[mW2d3XlckBRWkxiYX7kJGJu[WxzIHX4dJJme3Orb36= Mmf6NlU4OjdyMUi=
GH3 Mkm4SpVv[3Srb36gRZN{[Xl? M{jUelHDqM7:TR?= MlGwOk1p NYLBU45McW6mdXPld{BRWkxiYX7kJGJu[WxzLDDieZQhdm:2IFPsc4NsNCCvUl7BJIV5eHKnc4Ppc44> MljUNlU4OjdyMUi=
BeWo MoDSSpVv[3Srb36gRZN{[Xl? M1LCd|Ex6oDMzszNxsA> MYm3NkBp NYTpOXpDTE2VTx?= MUnt[YRq[XSnczDC[XdwKGOnbHyg[Iln\mW{ZX70bYF1cW:w Mm\BNlU4OTN2MkW=
oocytes M1nyXmZ2dmO2aX;uJGF{e2G7 MXK1JO69VQ>? MlvCNlQhcA>? NUXncm9W[XS2ZX71ZZRmeyC{aD3pcpN2dGmwIHHjeIlwdiCxbjDvc4N6fGViR2\CSEB{cWewaX\pZ4FvfGy7wrC= NXrjdlFSOjV5MEe4OVQ>
SC Moj1SpVv[3Srb36gRZN{[Xl? MWOwMlUh|ryP NFmySGEzPCCq MYftbY1q[2u|IITo[UBm\m[nY4Sgc4Yh[0GPUDDhcoFtd2e|IH;uJG8yKGGwZDDNRnAh\XiycnXzd4lwdg>? M4Pwb|I2PzB3OEe0
SC MVPGeY5kfGmxbjDBd5NigQ>? NWHrUFJvOC53IN88US=> NEH5WHY4OiCq NXvmS5E5cW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=> MYGyOVcxPTh5NB?=
UACC-647  NIj3SI5HfW6ldHnvckBCe3OjeR?= MWHEUXNQ M3uyV4xm[WS|IITvJIEhemm|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN|nDqM7:TTm= M1LsRVI2PzB|MEK1
UACC-647  MmTLSpVv[3Srb36gRZN{[Xl? MkWxNVDDqM7:TR?= NH\iSmQyPSCvaX6= M4n5TmROW09? MW\pcohq[mm2czDFVmsheGixc4Doc5J6dGG2aX;u NUDZfIJoOjV5MEOwNlU>
UACC-647  NWnXdJVlTnWwY4Tpc44hSXO|YYm= NHjnWWUyOMLizszN MnvxNVUhdWmw NXqydZJiTE2VTx?= NIfteo5qdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB? NY\3fGNWOjV5MEOwNlU>
SH-SY5Y  NU\1TYpUTnWwY4Tpc44hSXO|YYm= MmGzNVDDqM7:TR?= NGW1O40yyqCqwrC= NV3HR2hIcW6lcnXhd4V{KEyXQzDhZ5Rqfmm2eR?= M3H0clI2PTl5NEOz
SH-SY5Y  NXza[ZVPTnWwY4Tpc44hSXO|YYm= NUXo[WxROTEEoN88US=> M1T4e|HDqGkEoB?= NEjVU|dqdmO{ZXHz[ZMhSUeFMTDtVm5CKGyndnXs NVvUTY97OjV3OUe0N|M>
hADSCs MYPGeY5kfGmxbjDBd5NigQ>? MVu15qCKyrWP M1GwRVMxKG2rbh?= M1\XbYlv[3KnYYPld{BkSU2SIHzleoVtew>? NF;iW3kzPTV7MUmwPC=>
HEK293  M32xWWZ2dmO2aX;uJGF{e2G7 NVK1WGtVPeLCidM1US=> MUGzNEBucW5? NXXzOHZ6cW6lcnXhd4V{KGODTWCgcIV3\Wy| NHuybXgzPTV7MUmwPC=>
3T3-L1 NIHGUXFHfW6ldHnvckBCe3OjeR?= MWeyMlUwPSEQvF2= NGjveHozPCCqwrC= NYHuUVN7e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRXRIVCCycn;0[YlvKGW6cILld5Nqd25iYYSgZYxtKGSxc3XzJJRme3SnZB?= MnjVNlU2QTB3OUe=
OCI-Ly1  MU\GeY5kfGmxbjDBd5NigQ>? M{jmWVQxyqEQvF2= MmqwNeKhcMLi MkGxSG1UVw>? NIDoVVNqdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> NWn0ZYdYOjV3N{[yNlA>
OCI-Ly18  M4DH[WZ2dmO2aX;uJGF{e2G7 MkKwOFDDqM7:TR?= MYqxxsBpyqB? NICySZJFVVOR MXPpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= MlPxNlU2PzZ{MkC=
BeWo Ml3zSpVv[3Srb36gRZN{[Xl? NFvJfZczOMLiwsXN NYfPb5dDPDkEoHi= NUTKTpFPTE2VTx?= NWDMUZVicW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> MWqyOVU3Pjd2MB?=
BeWo NHzLPWpHfW6ldHnvckBCe3OjeR?= NYj6dlFUOjEEoNM1US=> M3K0flQ5yqCq NIPCSlNFVVOR Mn34bY5kemWjc3XzJJRp\SCjZHjld4lwdiCxZjDUTHAuOSCvb37vZ5l1\XN? MVWyOVU3Pjd2MB?=
LNCaP  NEW0WHpHfW6ldHnvckBCe3OjeR?= NVrDWWNNOTEEoN88US=> NUGzcpcyOTJiaNMg NYCxSI5pTE2VTx?= MmDWbY5lfWOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJI9nKEOURVKxJIFkfGm4aYT5 NXfLTFI3OjV3NEiwPVk>
ThGCs  MYTGeY5kfGmxbjDBd5NigQ>? MWGxNQKBks7:TR?= NE\EelM16oDMaB?= MoG0ZZVodWWwdIOgTGlHOUFibHX2[Yx{KHSqYYSge4Vz\SC|dHnteYxifGWmIHL5JGNwS2x{ M1XkdFI2PDN|MEK3
ThGCs  MlOwSpVv[3Srb36gRZN{[Xl? MXyxNQKBks7:TR?= NE\lXG016oDMaB?= M3Wwbolv[3KnYYPld{BEd0OuMj3pcoR2[2WmIFXEUlLDqGenbnWg[ZhxemW|c3nvci=> Mn3GNlU1OzNyMke=
ThGCs  MV7GeY5kfGmxbjDBd5NigQ>? NFrYOGoyOOLCit88US=> NX\FblhDOyCq NFruWYlqdmirYnn0d{B1cGViZX\m[YN1KG:oIFiyU|Ihd25iRVTONkBuWk6D M{\OUlI2PDN|MEK3
RBMECs M{PaXWZ2dmO2aX;uJGF{e2G7 M3OzflAvODVxMD61M|Uh|ryP M{Dab|AvOjViaB?= NGDwWoxqdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v MnvSNlU1OTZ4NUG=
RBMECs NX;sOZhnTnWwY4Tpc44hSXO|YYm= M{nlelXDqM7:TR?= MmntNUBp MXficI9kc3NidHjlJIFkfGm4YYTpc44hd2ZiUnjvRU9TV0ONIHnu[JVk\WRiYomgSW1CWC2LSR?= M1yzeVI2PDF4NkWx
RBMECs MkH0SpVv[3Srb36gRZN{[Xl? M3TNO|XDqM7:TR?= M3HWTlEhcA>? M4nBR5Bz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? M3f6[lI2PDF4NkWx
RBMECs MYfGeY5kfGmxbjDBd5NigQ>? MXq1xsDPxE1? Ml;4NUBp NYHKS3VzeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJGhTWCCobIX4JIFkem:|czD0bIUhSlSEIHnu[JVk\WRiYomgJGVOSVBvSVm= Ml60NlU1OTZ4NUG=
RBMECs MnfZSpVv[3Srb36gRZN{[Xl? NH;0[|k2yqEQvF2= MljnNUBp MXjpcohq[mm2czD0bIUh\GWlcnXhd4VlKG:oIHHtc5VvfCCxZjDaU{0yKGmwIF3Gd{BqdmS3Y3XkJIJ6KEWPQWCtTWk> NWPG[mJOOjV2MU[2OVE>
RBMECs MWXGeY5kfGmxbjDBd5NigQ>? NYDxO5lLPcLizszN MXyxJIg> MmTidoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 NFq3d4MzPTRzNk[1NS=>
RBMECs M1zzc2Z2dmO2aX;uJGF{e2G7 M1rPSVXDqM7:TR?= NVXocVk{OSCq MULicI9kc3NidHjlJGVOSVBvSVmtbY5lfWOnZDDjbIFv\2ViaX6gUWxEKHCqb4PwbI9zgWyjdHnvci=> NGTSS|czPTRzNk[1NS=>
RBMECs NWXLZnhnTnWwY4Tpc44hSXO|YYm= MWO1xsDPxE1? M33I[lEhcA>? MXricI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg MWqyOVQyPjZ3MR?=
Primary bovine chondrocytes M{\kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPUOe69VQ>? MnrROFghcA>? NHfleYRz\X[ncoPld{B1cGViaX7obYJqfG:{eTDl[oZm[3Rib3[gZ4Vt\WOxeHniJI9vKHC{b3zp[oVz[XSrb36gbY4h\3Kxd4ToJJBt[XSnIHPoc45lem:leYTldy=> NVz6SFBEOjV2ME[wNVY>
EM1  NV72XZptTnWwY4Tpc44hSXO|YYm= NXLJb25POTYkgJtOwG0> M{DJXFQ5KGh? NV72[G4xemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR|Iue2muZX7j[YQhTU1zIHPlcIx{yqB? NVnLZ2J[OjV|N{i2OlE>
BeWo  Mm\JSpVv[3Srb36gRZN{[Xl? M2jHcVIxyqEEtV2= MlPMOFjDqGkEoB?= M1TWVmROW00EoB?= NHXXSlhqdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? MUmyOVM3OjJ4MB?=
BeWo  M2fFe2Z2dmO2aX;uJGF{e2G7 NIn6O4EzOMLiwsXN MmDnOFjDqGkEoB?= MmDBSG1UV8Li NFy5NZZld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 MXOyOVM3OjJ4MB?=
BeWo  M3zXeWZ2dmO2aX;uJGF{e2G7 M{DGd|IxyqEEtV2= NF63dVc1QMLiaNMg NGP4OHJFVVORwrC= MWnkc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDHR20uOQ>? MXiyOVM3OjJ4MB?=
granulosa cells NIL3XZlHfW6ldHnvckBCe3OjeR?= NWjpZXR6OTBizszN M3PlSFEzNzJ2IHi= NF;Z[VJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=> NH\3U20zPTN|OUGwOS=>
granulosa cells MoewSpVv[3Srb36gRZN{[Xl? NF;P[mUyOCEQvF2= MoLCNVIwOjRiaB?= NI\MfGtqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDy[ZBwenSncjDhZ5Rqfmm2eTDmc5IhfGinIHzvcodme3RiZoLh[41mdnRiKPMIllg2PC9tMUjSS3MzNkyXQzm= NGjMNFQzPTN|OUGwOS=>
granulosa cells M1vYXGZ2dmO2aX;uJGF{e2G7 NYXCPGV6OTBizszN M2jiW|I1KGh? NXzqd5RbcW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhTE6DL4Dyc5RmcW5iY3;tdIxmgA>? NVTrdoY1OjV|M{mxNFU>
granulosa cells MVTGeY5kfGmxbjDBd5NigQ>? NWjPN4JmOTBizszN NF;zR4IzPCCq M1TmbIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> NHq4O2kzPTN|OUGwOS=>
SK-N-AS  NFrXNJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnfNNVAh|ryPwrC= NYOweHV2OjRxNEigbC=> NWiwVYhY\W6qYX7j[ZMhfGmvZT3k[ZBmdmSnboTsfUBk\WyudXzhdkB3cWGkaXzpeJnDqA>? NGH1dHMzPTJ4NkC2Ny=>
SK-N-AS  MkLISpVv[3Srb36gRZN{[Xl? MUmxNEDPxE4EoB?= M3;5e|I1KGh? MlnObY5kemWjc3XzJJRp\SClQV3QJIxmfmWuc9Mg NYTDSIlzOjV{Nk[wOlM>
SK-N-AS  MYrGeY5kfGmxbjDBd5NigQ>? Mm\WNVAh|ryPwrC= M{iyVVI1KGh? NVz1[IsycW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGO7Y3zpckBFOQ>? M2j1UlI2OjZ4ME[z
SK-N-AS  Mlm3SpVv[3Srb36gRZN{[Xl? MUKxNEDPxE4EoB?= NHzTboM{OCCvaX6= NH\iSmJqdmS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kDPui2lYYTlcolvKCi|ZYK2O|UqNCCyLVfTT|PPuiBqc3XyPUkh[W6mIHPvcoNwdWm2YX70JIhq\2incjDs[ZZmdHNib3[gZYN1cX[nLDD1cpBpd3OyaH;yfYxifGWmLDFOtk1k[XSnbnnu NXztT4ltOjV{Nk[wOlM>
SK-N-AS  MV\GeY5kfGmxbjDBd5NigQ>? M4LBNFExKM7:TdMg NYG5cFJNOTBxM{CvOlAhdWmw NWraVId4cW6lcnXhd4V{KGyndnXsd{Bw\iCyLd8yMYNifGWwaX6gLJNmejZ5NTmgZY5lKGmwZIXj[ZMh[WOldX31cIF1cW:wIH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCrbjCodIVzcSmwdXPs[YFzKHKnZ3nvcpM> NGTzS44zPTJ4NkC2Ny=>
SK-N-SH NWLo[|FQS2WubDDWbYFjcWyrdImgRZN{[Xl? NF\HRoUyOCEQvF5CpC=> MXW0PEBp NGK3O3VmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk> NX7r[WVKOjV{Nk[wOlM>
HEK‐CFTR NVLrfpN1TnWwY4Tpc44hSXO|YYm= NWPIVG9lOuLCk{WwxsDPxE1? NWXSd486OC1zMjDtbY4> MY\EUXNQyqB? NEexdVNqdmS3Y3XzJIEh\G:|ZfMAlIRmeGWwZHXueEBqd2SrZHWg[YZndHW6wrC= NGDHdZQzPTJ4M{KwOy=>
L6 MVvGeY5kfGmxbjDBd5NigQ>? MknPOFAhyrWP M3T5cVI1KGh? M4rQXolvcGmkaYTzJGROUDFvaX7keYNm\CCDa4SgZYN1cX[jdHnvci=> MkfYNlUzPDd3NUC=
MIN6  NGXUOpJHfW6ldHnvckBCe3OjeR?= M2nWXVExKM7:TdMg MoLFN{Bp M1vxfIlv[3KnYYPld{BFOyCvUl7BJIV5eHKnc4Ppc44> Mkn0NlUzPDFzMkS=
ventricular cardiomyocytes  MUnGeY5kfGmxbjDBd5NigQ>? MlXPNE4xOS1zMDFOwG0> NEfGd3hqdmO{ZXHz[ZMhKGODTWCgZYNkfW23bHH0bY9v NYDuXlk5OjV{MEOxNVM>
ventricular cardiomyocytes  MVjGeY5kfGmxbjDBd5NigQ>? MWKwMlAyNTFyIN88US=> NE[3RnZmfm:tZYOgZY4hcW6xdILvdIlkKHKnc4DvcpNmKDF{MNMxNVUmKGGkb4\lJIJie2GuIIfpeIgh[W5iRVO1NOKhd2ZiMj6yJOK2VQ>? MWCyOVIxOzFzMx?=
BeWo  MUXGeY5kfGmxbjDBd5NigQ>? NFjCPWUzOCEEtV2= NETyR3I1QCCq M2nlXmROW00EoB?= MlnKbY5lfWOnczDj[YxtKG[3c3nvci=> NUftT2pUOjVzOES0O|c>
THP-1  MUjGeY5kfGmxbjDBd5NigQ>? NEnTSmgyNzFyIN88US=> MlvBNuKhcA>? MlXPSG1UV8Li MYnzeZBxemW|c3XzJG1EWC1zIIDyc4R2[3Srb39CpC=> NH;mb4gzPTF3NEi4Ni=>
Huh-7 NVS0VXZrTnWwY4Tpc44hSXO|YYm= MnrxNE0zOCEQvF2= MmTZNkBpyqB? NVL6eJdJemW|dXz0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KGmwY4LlZZNmKGmwIHOtUZlkKGW6cILld5Nqd25iYYSgeIhmKHC{b4TlbY4h[W6mIH3SUmEhdGW4ZXzz NWjlc5V4OjVzMEm4N|Q>
C6 NX;TVG46TnWwY4Tpc44hSXO|YYm= M1nMN|ExKM7:TdMg NGTWRYUzOCCvaX6= MWfpcoNz\WG|ZYOgZ2FOWCCjY3P1cZVt[XSrb36= NFPu[HkzPTB4OUSxOy=>
SW480 MXPGeY5kfGmxbjDBd5NigQ>? MVq0NOKh|ryP MXi0POKhcA>? NUTjdW83TE2VTx?= NXHlWZBi[WO2aY\heIV{KFCSMlG= MUGyOFk6PzR3MR?=
HT-29  Ml7ISpVv[3Srb36gRZN{[Xl? Mny2OFDDqM7:TR?= MlHYOFjDqGh? NXXLVXNyTE2VTx?= NXfFb3dz[WO2aY\heIV{KFCSMlG= NVftUolMOjR7OUe0OVE>
SW480 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPae4NUPDEEoN88US=> MUKwMVczKGh? MlPzSG1UVw>? NHW1c4pqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 M1S4dVI1QTl5NEWx
HT-29  NH7mc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK0NOKh|ryP NYe1SWxXOC15MjDo MVHEUXNQ MWPpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NYHLUYYzOjR7OUe0OVE>
SW480 M4H6c2Z2dmO2aX;uJGF{e2G7 M1XwcFQxyqEQvF2= NHTNZYs4KGR? M3qz[WROW09? NWHZToJYemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> MoHWNlQ6QTd2NUG=
HT-29  MmDOSpVv[3Srb36gRZN{[Xl? NVfsVItFPDEEoN88US=> MVu3JIQ> M1X1[2ROW09? NVm2eodoemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> M2PNS|I1QTl5NEWx
SW480 MkDqRZBweHSxc3nzJGF{e2G7 NFz1UFQ1OMLizszN MYq0POKhcA>? M{TDXmROW09? MUPpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= MWiyOFk6PzR3MR?=
HT-29  MX7BdI9xfG:|aYOgRZN{[Xl? NED1SWM1OMLizszN MVS0POKhcA>? NX7KRld2TE2VTx?= NFv3blRqdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> M3\kTlI1QTl5NEWx
SW480 MX3BdI9xfG:|aYOgRZN{[Xl? M3nDSlQxyqEQvF2= NWqwTFhtPDkEoHi= NUGx[mtDTE2VTx?= NEPnW2hqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz MY[yOFk6PzR3MR?=
HT-29  MYjBdI9xfG:|aYOgRZN{[Xl? NGnKOnM1OMLizszN NXTLTXNwPDkEoHi= NEDIbphFVVOR NHnYU3lqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz MYeyOFk6PzR3MR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

Protocol

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
Synonyms Coleonol

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

cAMP Signaling Pathway Map

Tags: buy Forskolin | Forskolin supplier | purchase Forskolin | Forskolin cost | Forskolin manufacturer | order Forskolin | Forskolin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID